September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy

by | Oct 7, 2021

Top Biopharma Partnership by Upfront Cash and Equity

September 2021

REGENXBIO development and commercialization deal with AbbVie for RGX-314

Announced: September 13, 2021

Total Deal Value: $1,750M

Upfront Cash: $370M

Upfront Equity: n/a

Option Payments: n/a

Milestones: $1,380M (Dev., Reg., and Sales)

Royalty: Tiered ex-U.S.

Cost and Profit Split: 50% in U.S.

The Asset:

Phase II RGX-314 for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other chronic retinal diseases.

Deal Structure:

Development and Commercial License

Partnership Features:

Co-Development and co-promotion option.

The Details:

  • REGENXBIO granted AbbVie exclusive, worldwide rights to develop and commercialize RGX-314 for the treatment of wet AMD, diabetic retinopathy, and other chronic retinal diseases.
  • REGENXBIO will be responsible for completion of the ongoing trials.
  • AbbVie and REGENXBIO will share costs on additional trials, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials.
  • AbbVie will lead the clinical development and commercialization globally.
  • REGENXBIO will participate in U.S. commercialization efforts under a mutually agreed upon plan.
  • REGENXBIO will receive $370M up front and is eligible for up to $1.38B in development, regulatory, and commercial milestones, plus tiered royalties on net sales of RGX-314 outside the U.S. and 50% of profits in the U.S.

Last Month:

The Deal of the Month for August 2021 was RemeGen and Seagen’s HER2 ADC deal with $200M up front for Disitamab Vedotin. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting to schedule your personalized demo.

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.


Deal Profiles


Funding Rounds


Company Profiles


Product Profiles


Clinical Trials


Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

Get more done.

Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.

More Research by DealForma

Biotech Companies in Major Industry Centers Rake in the Cash

Biotech Companies in Major Industry Centers Rake in the Cash

Location, Location, Location: Real estate costs a lot in the three largest biotech hubs, but it’s a charm for raising capital. Biotech companies raised $37.4 billion globally in 1027 rounds of venture financing over the past four years from 2015 through the third quarter of 2018 and companies located in the San Francisco Bay Area, greater Boston area, and San Diego County accounted for 55 percent of the total raised and 46 percent of the financing activity.

read more

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.